Asana BioSciences Relocates Operations To Lawrenceville, New Jersey
08/24/2016
“This move was necessary to further our vision of building an oncology-focused biopharmaceutical company,” said Sandeep Gupta, Ph.D., president and chief executive officer of Asana BioSciences. “As we continue to expand and grow, our new Princeton area location makes it ideal for us to attract key scientific and medical talent within the Central New Jersey and Philadelphia life sciences corridor.”
According to company officials, Asana continues to advance its portfolio of differentiated targeted therapies to help address major unmet medical needs, including a novel CYP17 inhibitor for prostate cancer and a dual Syk/JAK inhibitor for non-Hodgkin’s lymphoma that are in phase I/II clinical trials.
Asana BioSciences, an independent member of The Amneal Alliance of companies, is a research and development company, specializing in the discovery and development of novel drug candidates, including an antibody-drug conjugate. Asana’s portfolio consists of multiple early-stage development candidates in a variety of therapeutic areas, including oncology, pain and inflammation, among others. Over the past year, it has been adding key talent to its team, including the appointment of a chief medical officer and expansion of its scientific advisory board.
Project Announcements
ContiTech Expands Mount Pleasant, Iowa, Production Operations
12/07/2025
Modular Closets Plans Kernersville, North Carolina, Production Operations
12/07/2025
QMP Plans Walterboro, South Carolina, Operations
12/06/2025
Ninth Avenue Foods Plans Longview, Texas, Production Operations
12/06/2025
LayerZero Power Systems Expands Streetsboro, Ohio, Manufacturing Operations
12/06/2025
BioStem Technologies Plans Boca Raton, Florida, Headquarters Operations
12/06/2025
Most Read
-
Rethinking Local Governments Through Consolidation and Choice
Q3 2025
-
First Person: Filter King’s Expansion Playbook
Q3 2025
-
Rethinking Auto Site Strategy in the Age of Tariffs and Powertrain Shifts
Q3 2025
-
Lead with Facts, Land the Deal
Q3 2025
-
How Canada Stays Competitive
Q3 2025
-
America’s Aerospace Reboot
Q3 2025
-
The Permit Puzzle and the Path to Groundbreaking
Q3 2025